The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
Official Title: An Open-Label Multi-Center Phase Ib/II Study of the Combination of AK105 and Anlotinib Hydrochloride in the First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma
Study ID: NCT04172571
Brief Summary: This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chinese PLA General Hospital, Beijing, Beijing, China
Name: Shunchang Jiao, MD
Affiliation: Chinese PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Li Bai, MD
Affiliation: Chinese PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR